NeuroPace director granted shares and stock options

NeuroPace Inc director Renee Ryan received new equity awards as part of compensation.

Rhea-AI Filing Summary

NeuroPace Inc director Renee Ryan received new equity awards as part of compensation. She was granted 2,890 shares of common stock at no cost, bringing her direct common stock holdings to 2,890 shares after the transaction.

She also received stock options for 5,368 shares of common stock at an exercise price of $15.74 per share, with 5,368 options held after the grant. Both the share grant and the options vest in twelve equal consecutive monthly installments, conditioned on her continuous service through each vesting date, and the options expire on June 4, 2036.

Insider Trade Summary

Grant/Award: 8,258 shares

Grant/Award 2 txns

Insider Ryan Renee

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,368	$0.00	$0.00
Grant/Award	Common Stock	2,890	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,368 contracts (Direct); Common Stock — 2,890 shares (Direct)

Footnotes (2)

1. F1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.
2. F2. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Common shares granted: 2,890 shares Options granted: 5,368 options Option exercise price: $15.74 per share +2 more

5 metrics

Common shares granted 2,890 shares Director equity award, holdings after grant

Options granted 5,368 options Stock Option (Right to Buy) held after grant

Option exercise price $15.74 per share Exercise price for 5,368 stock options

Option expiration June 4, 2036 Expiration date of stock options

Vesting schedule length 12 months Monthly vesting for shares and options

Key Terms

stock option, exercise price, vesting, expiration date

4 terms

stock option financial

"Stock Option (Right to Buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "15.7400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares shall vest in twelve (12) equal consecutive monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeuroPace (NPCE) director Renee Ryan report in this Form 4?

Renee Ryan reported receiving equity compensation from NeuroPace. She was granted 2,890 shares of common stock and stock options for 5,368 shares, reflecting routine director compensation rather than open-market buying or selling activity.

How many NeuroPace (NPCE) common shares does Renee Ryan hold after this filing?

After the reported grant, Renee Ryan holds 2,890 shares of NeuroPace common stock directly. These shares were granted at no cost as part of her compensation and will vest over time subject to her continued service on the board.

What stock options did Renee Ryan receive from NeuroPace (NPCE)?

Renee Ryan received stock options covering 5,368 NeuroPace common shares at an exercise price of $15.74 per share. All 5,368 options are reported as held after the grant and expire on June 4, 2036, subject to vesting conditions.

How do the NeuroPace (NPCE) equity awards to Renee Ryan vest?

Both the common stock grant and the stock options vest in twelve equal monthly installments. Vesting continues until all shares and options are fully vested, but requires Renee Ryan’s continuous service with NeuroPace through each monthly vesting date.

Does this NeuroPace (NPCE) Form 4 show insider buying or selling in the market?

No, this Form 4 shows compensation-related grants, not market trades. The reported transactions are award acquisitions of shares and options at no cost, rather than open-market purchases or sales of NeuroPace stock by Renee Ryan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Renee

(Last) (First) (Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW CALIFORNIA 94043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		2,890(1)	A	$0	2,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.74	06/05/2026		A		5,368		(2)	06/04/2036	Common Stock	5,368	$0	5,368	D

Explanation of Responses:

1. The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.

2. The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)